Cognitive impairment and dementia in patients with Parkinson disease

James B. Leverenz; Joseph F. Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S. Montine; Thomas J. Montine

doi:10.2174/156802609789378218

Cognitive impairment and dementia in patients with Parkinson disease

James B. Leverenz, Joseph F. Quinn, Cyrus Zabetian, Jing Zhang, Kathleen S. Montine, Thomas J. Montine

Neurology

Research output: Contribution to journal › Review article › peer-review

61 Scopus citations

Abstract

Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.

Original language	English (US)
Pages (from-to)	903-912
Number of pages	10
Journal	Current topics in medicinal chemistry
Volume	9
Issue number	10
DOIs	https://doi.org/10.2174/156802609789378218
State	Published - 2009

Keywords

Alzheimer disease
Cognitive impairment
Demenita with Lewy bodies
Dementia
Parkinson disease

ASJC Scopus subject areas

Drug Discovery

Access to Document

10.2174/156802609789378218

Cite this

@article{1d5a91107f06400d92fc7d7d4e6ac26b,

title = "Cognitive impairment and dementia in patients with Parkinson disease",

abstract = "Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.",

keywords = "Alzheimer disease, Cognitive impairment, Demenita with Lewy bodies, Dementia, Parkinson disease",

author = "Leverenz, {James B.} and Quinn, {Joseph F.} and Cyrus Zabetian and Jing Zhang and Montine, {Kathleen S.} and Montine, {Thomas J.}",

year = "2009",

doi = "10.2174/156802609789378218",

language = "English (US)",

volume = "9",

pages = "903--912",

journal = "Current topics in medicinal chemistry",

issn = "1568-0266",

publisher = "Bentham Science Publishers B.V.",

number = "10",

}

TY - JOUR

T1 - Cognitive impairment and dementia in patients with Parkinson disease

AU - Leverenz, James B.

AU - Quinn, Joseph F.

AU - Zabetian, Cyrus

AU - Zhang, Jing

AU - Montine, Kathleen S.

AU - Montine, Thomas J.

PY - 2009

Y1 - 2009

N2 - Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.

AB - Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.

KW - Alzheimer disease

KW - Cognitive impairment

KW - Demenita with Lewy bodies

KW - Dementia

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=74249120831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249120831&partnerID=8YFLogxK

U2 - 10.2174/156802609789378218

DO - 10.2174/156802609789378218

M3 - Review article

C2 - 19754405

AN - SCOPUS:74249120831

SN - 1568-0266

VL - 9

SP - 903

EP - 912

JO - Current topics in medicinal chemistry

JF - Current topics in medicinal chemistry

IS - 10

ER -

Cognitive impairment and dementia in patients with Parkinson disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this